These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19572629)

  • 1. Eradication of CD19+ leukemia by targeted calicheamicin θ.
    Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
    Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
    Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma.
    Lode HN; Reisfeld RA; Handgretinger R; Nicolaou KC; Gaedicke G; Wrasidlo W
    Cancer Res; 1998 Jul; 58(14):2925-8. PubMed ID: 9679947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
    Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
    Uckun FM; Qazi S; Dibirdik I; Myers DE
    Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK; Frost P
    Curr Opin Pharmacol; 2003 Aug; 3(4):386-90. PubMed ID: 12901947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
    Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
    Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
    Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
    Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
    Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK
    Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
    Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
    Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
    Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.